CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization
Xuelu Peng, Runxia Gu, Tao Wang, Chuanmei Jiang, Haiyan Xing, Jie Meng, Tao Wen, Jianxiang Wang, Jian Liu, Haiyan Xu · 2026
Read CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization by Xuelu Peng, Runxia Gu, Tao Wang, Chuanmei Jiang, Haiyan Xing, Jie Meng, Tao Wen, Jianxiang Wang, Jian Liu, Haiyan Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13213746.txt.
Description
Xuelu Peng and co-authors design a two-in-one nanoparticle treatment for a hard-to-treat form of acute myeloid leukemia. The leukemia is driven by a fused protein, AML1-ETO, and by a surface receptor called CXCR4 that helps the cells survive. Their 2026 study packs a fat-based particle with a small RNA that silences the fused protein, and coats it with a peptide that blocks the receptor.
In a mouse model of stubborn disease and in a human leukemia cell line, the particles did both jobs at once. Leukemia cells matured into normal blood cell types, then died more readily when given the drug homoharringtonine. Treated mice lived much longer than untreated ones. The authors present the particle as a dual attack on two linked drivers of the disease.
Catalog record
| CREATOR | Xuelu Peng, Runxia Gu, Tao Wang, Chuanmei Jiang, Haiyan Xing, Jie Meng, Tao Wen, Jianxiang Wang, Jian Liu, Haiyan Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |